Аннотация
Микроокружение опухоли в настоящее время рассматривается как биомаркер выживаемости онкологических больных и играет важную роль при выборе оптимальной противоопухолевой терапии. Понимание происходящих в опухолевом микроокружении процессов и взаимодействий динамично совершенствуется, что открывает новые возможности для практической и исследовательской деятельности. В настоящем обзоре представлены данные о различных подходах к изучению некоторых параметров опухоль-инфильтрирующих лимфоцитов и других компонентов микроокружения опухоли как биомаркера прогноза клинических исходов и как инструмента для назначения рациональной терапии при колоректальном раке. Для подготовки обзора проведен поиск литературы по базам данных Scopus, Web of Science, Medline, PubMed, CyberLeninka, РИНЦ и CNKI. При анализе использованы источники, индексируемые в базах данных Scopus, Web of Science, PubMed; 68 % работ опубликовано за последние 5 лет. Использовано 37 источников для написания данного литературного обзора.
Библиографические ссылки
Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.-DOI: https://doi.org/10.3322/caac.21660.
Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008; 27(45): 5904-5912.-DOI: https://doi.org/10.1038/onc.2008.271.
Chen Y., Zheng X., Wu C. The role of the tumor microenvironment and treatment strategies in colorectal cancer. Front Immunol. 2021; 12: 792691.-DOI: https://doi.org/10.3389/fimmu.2021.792691.
Сагакянц А.Б., Дженкова Е.А., Мирзоян Э.А., et al. Основные и минорные популяции лимфоцитов: локальные особенности при различных стадиях рака ободочной кишки. Южно-Российский онкологический журнал. 2023; 4(1): 34-42.-DOI: https://doi.org/10.37748/2686-9039-2023-4-1-4. [Sagakyants A.B., Dzhenkova E.A., Mirzoyan E.A., et al. Major and minor populations of lymphocytes: local features in different stages of colon cancer. South Russian Journal of Cancer. 2023; 4(1): 34-42.-DOI: https://doi.org/10.37748/2686-9039-2023-4-1-4. (In Rus)].
Cha Y.J., Park E.J., Baik S.H., et al. Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy. Sci Rep. 2019; 9(1): 11617.-DOI: https://doi.org/10.1038/s41598-019-48140-1.
González I.A., Bauer P.S., Liu J., Chatterjee D. Intraepithelial tumour infiltrating lymphocytes are associated with absence of tumour budding and immature/myxoid desmoplastic reaction, and with better recurrence-free survival in stages I-III colorectal cancer. Histopathology. 2021; 78(2): 252-264.-DOI: https://doi.org/10.1111/his.14211.
Lang-Schwarz C., Melcher B., Haumaier F., et al. Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups. Hum Pathol. 2018; 79: 160-167.-DOI: https://doi.org/10.1016/j.humpath.2018.05.010.
Lugli A., Kirsch R., Ajioka Y., et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017; 30(9): 1299-1311.-DOI: https://doi.org/10.1038/modpathol.2017.46.
Lang-Schwarz C., Melcher B., Dregelies T., et al. Adjuvant chemotherapy in stage II and III colon cancer: the role of the «budding and TILs-(tumor-infiltrating lymphocytes) combination» as tumor-host antagonists. Int J Colorectal Dis. 2021; 36(8): 1765-1779.-DOI: https://doi.org/10.1007/s00384-021-03896-9.
Malietzis G., Giacometti M., Askari A., et al. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg. 2014; 260(2): 287-292.-DOI: https://doi.org/10.1097/SLA.0000000000000216.
Guinney J., Dienstmann R., Wang X., et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11): 1350-1356.-DOI: https://doi.org/10.1038/nm.3967.
Loree J.M., Pereira A.A.L., Lam M., et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 2018; 24(5): 1062-1072.-DOI: https://doi.org/10.1158/1078-0432.CCR-17-2484.
Hu F., Wang J., Zhang M., et al. Comprehensive analysis of subtype-specific molecular characteristics of colon cancer: specific genes, driver genes, signaling pathways, and immunotherapy responses. Front Cell Dev Biol. 2021; 9: 758776.-DOI: https://doi.org/10.3389/fcell.2021.758776.
Kong J.C., Guerra G.R., Pham T., et al. Prognostic impact of tumor-infiltrating lymphocytes in primary and metastatic colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum. 2019; 62(4): 498-508.-DOI: https://doi.org/10.1097/DCR.0000000000001332.
Shi W., Dong L., Sun Q., et al. Follicular helper T cells promote the effector functions of CD8+ T cells via the provision of IL-21, which is downregulated due to PD-1/PD-L1-mediated suppression in colorectal cancer. Exp Cell Res. 2018; 372(1): 35-42.-DOI: https://doi.org/10.1016/j.yexcr.2018.09.006.
Governa V., Trella E., Mele V., et al. The interplay between neutrophils and CD8+ T cells improves survival in human colorectal cancer. Clin Cancer Res. 2017; 23(14): 3847-3858.-DOI: https://doi.org/10.1158/1078-0432.CCR-16-2047.
Coppola A., Arriga R., Lauro D., et al. NK cell inflammation in the clinical outcome of colorectal carcinoma. Front Med (Lausanne). 2015; 2: 33.-DOI: https://doi.org/10.3389/fmed.2015.00033.
Väyrynen J.P., Haruki K., Lau M.C., et al. The prognostic role of macrophage polarization in the colorectal cancer microenvironment. Cancer Immunol Res. 2021; 9(1): 8-19.-DOI: https://doi.org/10.1158/2326-6066.CIR-20-0527.
Ge P., Wang W., Li L., et al. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer. Biomed Pharmacother. 2019; 118: 109228.-DOI: https://doi.org/10.1016/j.biopha.2019.109228.
Zhu H.F., Zhang X.H., Gu C.S., et al. Cancer-associated fibroblasts promote colorectal cancer progression by secreting CLEC3B. Cancer Biol Ther. 2019; 20(7): 967-978.-DOI: https://doi.org/10.1080/15384047.2019.1591122.
Monteran L., Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019; 10: 1835.-DOI: https://doi.org/10.3389/fimmu.2019.01835.
Gao Y., Sun Z., Gu J., et al. Cancer-associated fibroblasts promote the upregulation of PD-L1 expression through Akt phosphorylation in colorectal cancer. Front Oncol. 2021; 11: 748465.-DOI: https://doi.org/10.3389/fonc.2021.748465.
Becht E., de Reyniès A., Giraldo N.A., et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res. 2016; 22(16): 4057-4066.-DOI: https://doi.org/10.1158/1078-0432.CCR-15-2879.
Facciabene A., Motz G.T., Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012; 72(9): 2162-2171.-DOI: https://doi.org/10.1158/0008-5472.CAN-11-3687.
Quandt J., Arnovitz S., Haghi L., et al. Wnt-β-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression. Nat Immunol. 2021; 22(4): 471-484.-DOI: https://doi.org/10.1038/s41590-021-00889-2.
Zheng H., Bai Y., Wang J., et al. Weighted gene co-expression network analysis identifies CALD1 as a biomarker related to M2 macrophages infiltration in stage III and IV Mismatch repair-proficient colorectal carcinoma. Front Mol Biosci. 2021; 8: 649363.-DOI: https://doi.org/10.3389/fmolb.2021.649363.
Ten Hoorn S., de Back T.R., Sommeijer D.W., Vermeulen L. Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2022; 114(4): 503-516.-DOI: https://doi.org/10.1093/jnci/djab106.
Zhao Z., Yan N., Pan S., et al. The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma. Sci Rep. 2020; 10(1): 14126.-DOI: https://doi.org/10.1038/s41598-020-70985-0.
Дудаев З.А., Худоеров Д.Х., Мамедли З.З., et al. Непосредственные и отдаленные результаты лечения пациентов с раком средне и нижнеампулярного отделов прямой кишки с клиническим и патоморфологическим полным ответом после комбинированной терапии. Тазовая хирургия и онкология. 2022; 12(1): 41-48.-DOI: https://doi.org/10.17650/2686‑9594‑2022‑12‑1‑41‑48. [Dudayev Z.A., Khudoyerov D.Kh., Mammadli Z.Z., et al. Immediate and long-term results of treatment of patients with cancer of the middle and lower ampulla of the rectum with clinical and pathomorphological complete response after combination therapy. Pelvic Surgery and Oncology. 2022; 12(1): 41-48.-DOI: https://doi.org/10.17650/2686‑9594‑2022‑12‑1‑41‑48. (In Rus)].
Загидуллина А.А., Гордеев С.С., Мамедли З.З. Эффективность применения адъювантной химиотерапии у пациентов с перстневидноклеточным раком толстой кишки: ретроспективное исследование. Вопросы онкологии. 2023; 69(5): 871-875.-DOI: https://doi.org/10.37469/0507-3758-2023-69-5-871-875. [Zagidullina A.A., Gordeev S.S., Mamedli Z.Z. Efficacy of adjuvant chemotherapy in patients with ring-cell carcinoma of the large intestine: a retrospective study. Voprosy Onkologii = Problems in Oncology. 2023; 69(5): 871-875.-DOI: https://doi.org/10.37469/0507-3758-2023- 69-5-871-875. (In Rus)].
Li Y., Yao Q., Zhang L., et al. Immunohistochemistry-based consensus molecular subtypes as a prognostic and predictive biomarker for adjuvant chemotherapy in patients with stage II colorectal cancer. Oncologist. 2020; 25(12): e1968-e1979.-DOI: https://doi.org/10.1002/ONCO.13521.
De Guillebon E., Dardenne A., Saldmann A., et al. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. Int J Cancer. 2020; 147(6): 1509-1518.-DOI: https://doi.org/10.1002/ijc.32889.
Khaliq A.M., Erdogan C., Kurt Z., et al. Refining colorectal cancer classification and clinical stratification through a single-cell atlas. Genome Biol. 2022; 23(1): 113.-DOI: https://doi.org/10.1186/s13059-022-02677-z.
Karpinski P., Rossowska J., Sasiadek M.M. Immunological landscape of consensus clusters in colorectal cancer. Oncotarget. 2017; 8(62): 105299-105311.-DOI: https://doi.org/10.18632/oncotarget.22169.
Vanmeerbeek I., Sprooten J., De Ruysscher D., et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology. 2020; 9(1): 1703449.-DOI: https://doi.org/10.1080/2162402X.2019.1703449.
Zuo S., Wei M., He B., et al. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). EBioMedicine. 2021; 64: 103240.-DOI: https://doi.org/10.1016/j.ebiom.2021.103240.
Marei H.E., Althani A., Caceci T., et al. Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes. Biochem Pharmacol. 2019; 166: 335-346.-DOI: https://doi.org/10.1016/j.bcp.2019.06.002.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2024